Skip to content

A randomized controlled clinical trial of TACE in the treatment of HCC patients with MVI after radical resection

A randomized controlled clinical trial of TACE in the treatment of HCC patients with MVI after radical resection—clinical trial of postoperative TACE

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15007609
Enrollment
Unknown
Registered
2015-12-17
Start date
2015-12-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

TACE-group:twice the same project of TACE

Sponsors

The Second Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years, without restriction for gender, ethnic, religious, regional, etc.; 2. Underwent radical resection of liver cancer 1 month ago and postoperative pathological diagnosis is HCC with MVI; 3. Without complicated with other system malignant tumor; 4. MRI evidence shows no recurrence and metastasis before TACE; 5. Subjects are informed consent, understand and are willing to cooperate with testing scheme, sign the relevant documents.

Exclusion criteria

Exclusion criteria: 1. had any anti-tumor treatment before radical resection of liver cancer; 2. The pathological diagnosis is HCC; 3. The pathological diagnosis has MVI; 4. Had macro-vascular invasion; 5. The postoperative recovery is poor, has single or multiple organs failure; 6. Found metastasis or recurrence before TACE , or judged should not be treated with TACE.

Design outcomes

Primary

MeasureTime frame
The recurrence time;

Secondary

MeasureTime frame
The total survival time;

Countries

China

Contacts

Public ContactLi Jiangtao
zjulijiangtao@163.com+86 13666651245

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026